Immunoglobulin A Nephropathy

Immunology·MeSH: Glomerulonephritis, IGA

11 drugs in development·7 companies·14 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
Irbesartan	Travere Therapeutics, Inc. (TVTX)
ravulizumab	Hepion Pharmaceuticals, Inc. (CTRVP)
zigakibart	Novartis AG (NVS)

Phase 2(5)

Drug	Company
blisibimod	ANTHERA PHARMACEUTICALS INC (ANTH)
Felzartamab	BIOGEN INC. (BIIB)
sparsentan	Travere Therapeutics, Inc. (TVTX)
zaltenibart	OMEROS CORP (OMER)
zigakibart	Novartis AG (NVS)

Phase 4(3)

Drug	Company
Dapagliflozin	Travere Therapeutics, Inc. (TVTX)
No sparsentan	Travere Therapeutics, Inc. (TVTX)
ravulizumab	ALEXION PHARMACEUTICALS, INC. (ALXN)

BioSniper tracks 11 drugs in development for Immunoglobulin A Nephropathy across 7 companies.

There are 14 clinical trials targeting Immunoglobulin A Nephropathy tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.